Blood Testing for EML4-ALK Fusion Transcripts in Non-Small Cell Lung Cancer Patients by ddPCR: A CLIA Lab Experience Hestia Mellert, PhD April 17th, 2016

First Page		Document Content
Date: 2016-05-02 01:40:22 Lung cancer Tyrosine kinase receptors Piperidines Tyrosine kinase inhibitors Anaplastic lymphoma kinase Non-small-cell lung carcinoma Crizotinib T790M Alectinib KRAS Epidermal growth factor receptor Digital polymerase chain reaction		Blood Testing for EML4-ALK Fusion Transcripts in Non-Small Cell Lung Cancer Patients by ddPCR: A CLIA Lab Experience Hestia Mellert, PhD April 17th, 2016 Add to Reading List Source URL: www.biodesix.com Download Document from Source Website File Size: 959,80 KB Share Document on Facebook

	SUPPLEMENTARY INFORMATION: Specificity and mechanism-‐ of-‐action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348) 1. Deter DocID: 1rQNF - View Document
	CME A Look at the Near Future of Lung Cancer Treatment Dates of certification: May 31, 2016, to May 31, 2017 Medium: Print with online posttest, evaluation, and request for credit DocID: 1qVsW - View Document
	Pharmaceuticals and Medical Devices Agency This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English transl DocID: 1qEY9 - View Document
	ZAI Lab and Hanmi execute a license agreement to develop novel EGFR targeted therapy for lung cancer in China Shanghai, China and Seoul, Korea, 23th November 2015 – ZAI Lab Limited and Hanmi Pharm. Co., Ltd. announced DocID: 1qm1i - View Document
	TECHNOLOGY OFFER A COBALT-BASED STRATEGY FOR TUMOUR TARGETING OF EGFR-INHIBITORS BACKGROUND The development of receptor tyrosine-kinase inhibitors (TKIs) in recent DocID: 1pWe8 - View Document